Mark Lappe bought $2.6M of INBX
Chief Executive Officer at Inhibrx Biosciences, Inc.. 25,000 shares at an average of $105.82, traded Sep 8, 2026, filed Sep 8, 2026.
Score components
- +25RoleCEO
- +25Trade size$2.6M at market
- 0Relative to holdingsHoldings up 3.5%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001366074-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | POpen-market purchase Common Stockindirect: By the Lappe Family Trust | +5,895 | $99.29 | $585k | 711,443 | 36 d ago |
| Sep 8, 2026 | POpen-market purchase Common Stockindirect: By the Lappe Family Trust | +6,605 | $100.64 | $665k | 718,048 | 36 d ago |
| Sep 8, 2026 | POpen-market purchase Common Stockindirect: By the Lappe Family Trust | +1,100 | $107.12 | $118k | 719,148 | 36 d ago |
| Sep 8, 2026 | POpen-market purchase Common Stockindirect: By the Lappe Family Trust | +500 | $108.24 | $54k | 719,648 | 36 d ago |
| Sep 8, 2026 | POpen-market purchase Common Stockindirect: By the Lappe Family Trust | +1,219 | $111.88 | $136k | 720,867 | 36 d ago |
| Sep 8, 2026 | POpen-market purchase Common Stockindirect: By the Lappe Family Trust | +9,681 | $112.28 | $1.1M | 730,548 | 36 d ago |
Related signals
Other insiders at Inhibrx Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 63Notable | Inhibrx Biosciences, Inc. | Mark Lappe Chief Executive Officer | $999k 10,000 shares | +1% | |
| 46Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $500k 5,000 shares | +1% | |
| 53Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $500k 5,000 shares | +1% | |
| 31Weak | INBXsell Inhibrx Biosciences, Inc. | Kimberly Manhard director | $164k 1,500 shares | -17% | |
| 30Weak | INBXsell Inhibrx Biosciences, Inc. | Kimberly Manhard director | $115k 1,000 shares | -10% | |
| 44Moderate | Inhibrx Biosciences, Inc. | Douglas Forsyth director | $287k 2,500 shares | +1% | |
| 49Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $568k 5,000 shares | +1% | |
| 42Moderate | INBXsell Inhibrx Biosciences, Inc. | Viking Global Investors LP owner | $11M 350,000 shares | -22% | |
| 50Moderate | INBXbuy Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $1.5M 107,186 shares | +660% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.